4016.SR
4016.SR
SA160G51UO10
Middle East Pharmaceutical Indu
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 85/100, minimal insolvency risk). The high overall score (6/7) is driven primarily by extreme stock price swings (±24.2% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
6/7 High
6 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.5x
Defensive
Volatility (3Y p.a.)
24.2% p.a.
Fallback
Max Drawdown (3Y)
-32.2%
Fallback
Sharpe Ratio
-0.39
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -17.4%
3 Years 24.2% -32.2% -0.39 —
5 Years — — — —
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
ende